Among 12 patients with previously treated FLT3 mutated AML, 8 with prior FLT3 inhibitor exposure, all received FLT3 inhibitors along with decitabine and venetoclax achieving a CR/CRi rate of 42%, with MRD negativity by flow cytometry and PCR in half and quarter of responding patients respectively. This evidence concerns the gene FLT3 and acute myeloid leukemia.